Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
The active ingredient in JOURNAVX (suzetrigine) tablets is suzetrigine, a sodium channel blocker, which has the following chemical name:
4-[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-amido]pyridine- 2-carboxamide. Its molecular formula is C21H20F5N3O4.
Suzetrigine’s molecular weight is 473.39 g/mol. Suzetrigine has the following structural formula:
 |
Suzetrigine is a white to off-white solid and is practically insoluble in water.
JOURNAVX is available as a blue, film-coated tablet for oral administration containing 50 mg of suzetrigine and the following inactive ingredients: croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, and microcrystalline cellulose. The tablet film coat contains FD&C Blue #2 aluminum lake, polyethylene glycol, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.
JOURNAVX is indicated for the treatment of moderate to severe acute pain in adults.
Swallow JOURNAVX tablets whole and do not chew or crush.
The recommended starting dose of JOURNAVX is 100 mg orally. Take the starting dose on an empty stomach at least 1 hour before or 2 hours after food to avoid delay in onset of action [see CLINICAL PHARMACOLOGY]. Clear liquids may be consumed during this time (e.g., water, apple juice, vegetable broth, tea, black coffee).
Starting 12 hours after the initial dose, take 50 mg of JOURNAVX orally every 12 hours. Take these doses with or without food [see CLINICAL PHARMACOLOGY].
Avoid food or drink containing grapefruit during treatment with JOURNAVX [see DOSAGE AND ADMINISTRATION.
Use JOURNAVX for the shortest duration, consistent with individual patient treatment goals. Use of JOURNAVX for the treatment of moderate to severe acute pain has not been studied beyond 14 days.
The recommended dosage of JOURNAVX in patients with hepatic impairment is described in Table 1.
Table 1: Recommended JOURNAVX Dosage in Patients with Hepatic Impairment
| Degree of Hepatic Impairment (HI) | Recommended Dosage |
| Severe HI (Child-Pugh Class C) | Avoid use [see Use In Specific Populations]. |
| Moderate HI (Child-Pugh Class B) | Dose 1: The recommended starting dose of JOURNAVX is 100 ms taken orally. Take the starting dose on an empty stomach at least 1 hour before or 2 hours after food [see CLINICAL PHARMACOLOGY]. Clear liquids may be consumed during this time (e.g., water, apple juice, vegetable broth, tea, black coffee). Doses 2, 3, and 4: Starting 12 hours after the initial dose, take 50 mg of JOURNAVX orally every 12 hours. Take these doses with or without food [see CLINICAL PHARMACOLOGY]. Dose 5 and Subsequent Doses: Starting 12 hours after Dose 4, take 50 mg of JOURNAVX orally every 24 hours. Take these dose(s) with or without food [see CLINICAL PHARMACOLOGY]. |
| Mild HI (Child-Pugh Class A) | The recommended dosage is the same as in those with normal hepatic function [see DOSAGE AND ADMINISTRATION]. |
JOURNAVX is contraindicated in patients taking strong CYP3A inhibitors. When JOURNAVX is administered to patients taking moderate CYP3A inhibitors reduce the JOURNAVX dose, as described below:
Dose 1: The recommended starting dose of JOURNAVX is 100 mg orally. Take the starting dose on an empty stomach at least 1 hour before or 2 hours after food [see CLINICAL PHARMACOLOGY]. Clear liquids may be consumed during this time (e.g., water, apple juice, vegetable broth, tea, black coffee).
Doses 2, 3, and 4: Starting 12 hours after the initial dose, take 50 mg of JOURNAVX orally every 12 hours. Take these doses with or without food [see CLINICAL PHARMACOLOGY].
Dose 5 and Subsequent Doses: Starting 12 hours after Dose 4, take 50 mg of JOURNAVX orally every 24 hours. Take these dose(s) with or without food [see CLINICAL PHARMACOLOGY].
Avoid food or drink containing grapefruit during treatment with JOURNAVX [see DRUG INTERACTIONS, CLINICAL PHARMACOLOGY].
For patients on the standard recommended dosing schedule [see DOSAGE AND ADMINISTRATION]:
For patients with moderate hepatic impairment or patients taking moderate CYP3A inhibitors [see DOSAGE AND ADMINISTRATION], if a dose is missed, take the missed dose as soon as possible. If the next scheduled dose is within 6 hours, skip the next scheduled dose, and take the subsequent doses at the recommended time.
Tablets: 50 mg, blue, film-coated, oblong tablets debossed with “VX50” on one side and plain on the other.
JOURNAVX (suzetrigine) tablets are supplied as blue, film-coated, oblong tablets containing 50 mg of suzetrigine. Each tablet is debossed with the characters “VX50” on one side and plain on the other, and is packaged as follows:
30-count bottle NDC 51167-548-30
100-count bottle NDC 51167-548-31
100-count Hospital Unit Dose Carton (10 blister cards, each containing 10 tablets) NDC 51167-548-34
Store at 68°F to 77°F (20°C to 25°C); excursions permitted to 59°F to 86°F (15°C to 30°C) [see USP Controlled Room Temperature].
Manufactured for: Vertex Pharmaceuticals Incorporated; 50 Northern Avenue, Boston, MA 02210. Revised: Jan 2025
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety profile of JOURNAVX is primarily based on data from the pooled, double-blind, placebo- and active-controlled trials in 874 adult patients with moderate to severe acute pain following full abdominoplasty (Trial 1) and bunionectomy (Trial 2) [see Clinical Studies], with supportive safety data from one single arm trial in 256 adult patients with moderate to severe acute pain in a broad range of acute pain conditions (Trial 3).
In Trials 1 and 2, 874 patients received at least one dose of JOURNAVX. The proportion of patients in Trials 1 and 2 who discontinued study drug prematurely due to adverse events was:
The safety profile of JOURNAVX was also evaluated by the following subgroup analyses: age (≥ 18 to < 65 years and ≥ 65 years), sex, and race. Since most patients enrolled in the clinical trials were ≥ 18 to < 65 years of age, female, and white, there was insufficient data to detect differences in safety signals between these subgroups.
Table 2 displays adverse reactions that occurred more frequently in JOURNAVX-treated patients than placebo-treated patients in the pooled Trials 1 and 2.
Table 2: Adverse Reactions Reported in ≥1% of JOURNAVX-Treated Patients and Greater than Rate of Placebo in Two 48-hour Trials in Moderate to Severe Acute Pain (Trials 1 and 2, Pooled)
| Adverse Reactions (Preferred Term) | Placebo (N = 438) n (%) |
JOURNAVX (N = 874) n (%) |
HB/APAPa (N = 879) n (%) |
| Pruritus | 7 (1.6) | 18 (2.1) | 30 (3.4) |
| Muscle spasms | 2 (0.5) | 11 (1.3) | 6 (0.7) |
| Increased blood creatine phosphokinase | 2 (0.5) | 10 (1.1) | 7 (0.8) |
| Rash | 2 (0.5) | 10 (1.1) | 6 (0.7) |
| a Patients received 5 mg/325 mg of oral hydrocodone bitartrate/acetaminophen (HB/APAP) every 6 hours. | |||
In Trial 1, the incidence of patients who experienced either nausea or vomiting was 20% in JOURNAVX-treated patients, 33% in HB/APAP-treated patients, and 25% in placebo-treated patients. In Trial 2, the incidence of patients who experienced either nausea or vomiting was 9% in JOURNAVX-treated patients, 16% in HB/APAP-treated patients, and 12% in placebo-treated patients.
Creatine Phosphokinase Elevations
In Trials 1 and 2, 2.9% of JOURNAVX-treated patients and 1.2% of placebo-treated patients had a creatine phosphokinase (CPK) level > 3 times the upper limit of normal. The incidence of increased blood CPK was 1.1% in JOURNAVX-treated patients and 0.5% in placebo-treated patients. All reports of CPK elevations occurred in the post-surgical setting. There were no associated signs or symptoms, no serious adverse reactions, and no patients required treatment discontinuation or interruption.
Decreased Estimated Glomerular Filtration Rate
In Trials 1 and 2, 2.5% of JOURNAVX-treated patients and 0.9% of placebo-treated patients had a decrease in estimated glomerular filtration rate (eGFR) of ≥ 25% but < 50%. Follow-up eGFR data for these controlled trials was not available after treatment discontinuation. Similar decreases in eGFR also occurred in Trial 3 (the open-label Phase 3 study) and appeared to resolve to baseline by the final safety follow-up visit. There was no control arm for comparison. There were no adverse reactions of eGFR decrease in JOURNAVX-treated patients.
In an open-label study of patients with moderate to severe acute pain following a surgical procedure or nonsurgical condition [NCT05661734], a total of 256 adult patients received at least one dose of JOURNAVX. Patients received 100 mg as a first dose, then 50 mg every 12 hours and continued to receive JOURNAVX for up to 14 days or until their pain resolved. Rescue medication of 650 mg of acetaminophen and 400 mg of ibuprofen together every 6 hours was permitted as needed for pain relief. The patients’ perceptions of pain control was captured by patient global assessment (PGA). The mean duration of treatment with JOURNAVX was 9.6 days. The majority of patients were female (68%), and the median age was 43 years (range: 18 to 78).
In Trial 3, a total of 222 (87%) patients received JOURNAVX for post-surgical pain; orthopedic surgery was the most common (e.g., ligament operation, arthrodesis), followed by plastic surgery (e.g., liposuction, mammoplasty), otorhinolaryngologic surgery (e.g., nasal septal operation, turbinoplasty), and general and urologic surgery (e.g., inguinal hernia repair). Thirty-four (13%) patients received JOURNAVX for non-surgical pain (e.g., arthralgias, limb pain, and sprains/strains).
The proportion of patients who discontinued study drug prematurely was 2% due to adverse events (arrhythmia [0.4%], nausea [0.4%], somnolence [0.4%], rash [0.4%]) and 1.6% due to lack of efficacy.
The safety profile of JOURNAVX in Trial 3 was consistent with that observed in Trials 1 and 2.
Table 3 describes drug interactions where concomitant use of another drug affects the use of JOURNAVX.
Table 3: Drug Interactions: Concomitant Use of Other Drugs that Affect the Use of JOURNAVX
| Strong and Moderatea CYP3A Inhibitors | |
| Prevention or Management | Strong CYP3A inhibitors: Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated [see WARNINGS AND PRECAUTIONS]. |
| Moderate CYP3A inhibitors: Reduce the JOURNAVX dosage [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS]. | |
| Mechanism and Clinical Effect(s) | Suzetrigine and M6-SUZ are CYP3A substrates. Strong and moderate CYP3A inhibitors increase suzetrigine and M6-SUZ (active metabolite of suzetrigine) exposures [see CLINICAL PHARMACOLOGY], which may cause JOURNAVX adverse reactions. |
| Strong and Moderate CYP3A Inducers | |
| Prevention or Management | Avoid concomitant use of JOURNAVX with strong and moderate CYP3A inducers. |
| Mechanism and Clinical Effect(s) | Suzetrigine and M6-SUZ are CYP3A substrates. Concomitant use of strong or moderate CYP3A inducers results in reduced exposures of suzetrigine and M6-SUZ, which may result in reduced JOURNAVX efficacy [see CLINICAL PHARMACOLOGY]. |
| a Food or drink containing grapefruit should be avoided during treatment with JOURNAVX. | |
If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX [see WARNINGS AND PRECAUTIONS].
Suzetrigine is an inducer of CYP3A. Concomitant use with JOURNAVX may reduce the exposure of sensitive CYP3A substrates which may decrease the efficacy of these substrates. Discontinuation of JOURNAVX may increase the exposure of sensitive CYP3A substrates [see WARNINGS AND PRECAUTIONS, CLINICAL PHARMACOLOGY].
JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms), or use alternative contraceptives (such as a combined oral contraceptive containing ethinyl estradiol as the estrogen and levonorgestrel or norethindrone as the progestin, or an intrauterine system) during treatment with JOURNAVX and for 28 days after discontinuation of JOURNAVX [see WARNINGS AND PRECAUTIONS].
JOURNAVX did not result in clinically significant changes in the pharmacokinetics of ethinyl estradiol and levonorgestrel when used concomitantly with an oral contraceptive containing ethinyl estradiol and levonorgestrel [see CLINICAL PHARMACOLOGY].
Included as part of the PRECAUTIONS section.
Strong and moderate CYP3A inhibitors increase suzetrigine and M6-SUZ (active metabolite) exposures which may cause JOURNAVX adverse reactions. Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated [see DRUG INTERACTIONS, CLINICAL PHARMACOLOGY]. Reduce the JOURNAVX dosage with moderate CYP3A inhibitors [see DOSAGE AND ADMINISTRATION].
Suzetrigine is an inducer of CYP3A. If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage adjustment of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX [see DRUG INTERACTIONS, CLINICAL PHARMACOLOGY].
JOURNAVX-treated patients taking concomitant hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms) or use alternative contraceptives (e.g., a combined oral contraceptive containing ethinyl estradiol as the estrogen and levonorgestrel or norethindrone as the progestin, an intrauterine system) during JOURNAVX treatment and for 28 days after discontinuation of JOURNAVX [see DRUG INTERACTIONS, CLINICAL PHARMACOLOGY].
Patients with moderate hepatic impairment have higher systemic exposures of suzetrigine and M6-SUZ (active metabolite) than those with normal hepatic function which may increase the risk of JOURNAVX related adverse reactions [see Use In Specific Populations, CLINICAL PHARMACOLOGY].
Avoid use of JOURNAVX in patients with severe hepatic impairment (Child-Pugh Class C). The recommended JOURNAVX dosage is lower in patients with moderate hepatic impairment (Child-Pugh Class B) than those with normal hepatic function [see DOSAGE AND ADMINISTRATION].
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Ask patients to tell you all the medications they are taking, including any herbal supplements or vitamins [see DRUG INTERACTIONS].
Food or drink containing grapefruit should be avoided [see DOSAGE AND ADMINISTRATION, DRUG INTERACTIONS].
When used concomitantly with hormonal contraceptives containing a progestin other than levonorgestrel or norethindrone, advise patients to use an additional nonhormonal contraceptive (such as condoms) or use alternative contraceptives during JOURNAVX treatment and for 28 days after discontinuation of JOURNAVX [see DRUG INTERACTIONS].
Advise females of reproductive potential that JOURNAVX may reversibly impact the likelihood to become pregnant while on treatment. Patients using contraceptives should continue to use contraceptives [see Use In Specific Populations].
Inquire and/or assess whether patients have hepatic impairment.
Advise patients to take the starting dose of JOURNAVX on an empty stomach at least 1 hour before or 2 hours after food to avoid delay in onset of action. Clear liquids may be consumed (such as water, apple juice, vegetable broth, tea, or black coffee) during this time. Avoid food or drink containing grapefruit during treatment with JOURNAVX [see DOSAGE AND ADMINISTRATION].
Subsequent doses of JOURNAVX can be taken with or without food.
Patients should be instructed to swallow JOURNAVX tablets whole (do not chew or crush).
Inform patients about what to do in the event they miss a dose of JOURNAVX [see DOSAGE AND ADMINISTRATION].
Long-term animal studies have not been completed to evaluate the carcinogenic potential of suzetrigine.
Suzetrigine was not mutagenic in the bacterial reverse mutation assay (Ames test), or clastogenic in the in vitro micronucleus assay with a human TK6 lymphoblastoid cell line, or in the in vivo rat bone marrow micronucleus assay.
In a female fertility study, female rats were treated orally with suzetrigine at 5, 10, and 15 mg/kg/day for a minimum of 14 days prior to mating, throughout mating, and through Gestation Day 7. These doses are approximately 0.57, 1.6, and 2.2-times the steady state MRHD exposure based on AUC. Increased pre-implantation loss was observed at 15 mg/kg (approximately 2.2-times the MRHD based on AUC). The finding in rats may be explained by the effect of suzetrigine on the rat progesterone receptor, which was more sensitive to suzetrigine than the human progesterone receptor based on in vitro studies. Following 4-week withdrawal of treatment, there were no effects on female fertility and early embryonic development. The finding in the rat study is of uncertain relevance to humans. In a male fertility study, male rats were treated orally with suzetrigine at 200, 600, and 1000 mg/kg/day for a minimum of 28 days prior to mating and through mating. These doses are 3.6, 9.7, and 13.8-times the steady state MRHD exposure based on AUC, respectively. Suzetrigine had no effects on sperm parameters (motility, concentration, or morphology), reproductive performance or uterine parameters (number of implants, viable implants, pre-implantation loss, early resorptions, and post-implantation loss) at any dose.
There are no available data on the use of JOURNAVX during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
In animal reproduction studies in rats, effects on implantation and maintenance of pregnancy occurred at oral suzetrigine doses of ≥ 2.2-times the maximum recommended human dose (MRHD) when administered during early embryonic development or throughout organogenesis. In a pre- and postnatal development study, reduced mean gestation length and increased postnatal pup mortality were observed at maternal rat exposures of 1.6-times the MRHD and decreased rat pup body weights were observed during the period of birth to weaning at maternal exposures of 2.2-times the MRHD. No malformations were observed when suzetrigine was administered orally to rats and rabbits during the period of organogenesis at doses up to 2.2- and 5.9-times, respectively, the MRHD. The clinical relevance of these findings is unclear.
The background risk of major birth defects and miscarriage in patients with moderate to severe acute pain is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Animal Data
Suzetrigine was administered orally to pregnant rabbits during the period of organogenesis at 50, 100, and 200 mg/kg/day (approximately 1.6-, 3.1-, and 5.9-times, respectively, the steady state MRHD exposure based on AUC). Increased post-implantation loss and lower fetal body weight were observed at 200 mg/kg/day, which is a dose that also caused maternal toxicity. No adverse embryofetal effects were observed at doses up to 100 mg/kg.
Suzetrigine was administered orally to pregnant rats during the period of organogenesis at 5, 10, and 15 mg/kg/day (approximately 0.57-, 1.6-, and 2.2-times, respectively, the steady state MRHD exposure based on AUC). Increased post-implantation loss and lower number of live fetuses were observed at 15 mg/kg/day. No adverse embryofetal effects were observed at doses up to 10 mg/kg. Placental transfer of suzetrigine was observed in pregnant rats.
In a pre- and postnatal development study, suzetrigine was administered orally to pregnant rats at doses of 5, 10, and 15 mg/kg/day (approximately 0.57-, 1.6-, and 2.2-times, respectively, the steady state MRHD exposure based on AUC) from Gestation Day 6 through Lactation Day 20. Reduced mean gestation length and increased postnatal pup mortality between birth and Postnatal Day 4 were observed at ≥ 10 mg/kg and increased incidences of fully resorbed litters, lower live newborn pups, and reductions in pup body weights were observed at 15 mg/kg. No effects on learning and memory or sexual maturation were observed at dose up to 15 mg/kg/day.
The effects on implantation, maintenance of pregnancy, reduced mean gestation length, and increased postnatal pup mortality in rats are of uncertain relevance to humans.
There are no data on the presence of suzetrigine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Suzetrigine is present in animal milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for JOURNAVX and any potential adverse effects on the breastfed child from JOURNAVX or from the underlying maternal condition.
Advise patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone to use an additional nonhormonal contraceptive or to use alternative contraceptives during JOURNAVX treatment and for 28 days after discontinuation of JOURNAVX [see DRUG INTERACTIONS].
In a female fertility study in rats, increased pre-implantation loss was observed at oral suzetrigine doses of ≥ 2.2-times the MRHD when administered prior to mating and through Gestation Day 7. Following discontinuation of suzetrigine for 4 weeks, the increased pre-implantation loss in rats was not observed. The finding in rats may be explained by the effect of suzetrigine on the rat progesterone receptor, which was more sensitive to suzetrigine than the human progesterone receptor based on in vitro studies. The finding in the rat study is of uncertain relevance to humans.
JOURNAVX may reversibly impact the likelihood of females of reproductive potential to become pregnant while on treatment. Patients using contraceptives should continue to use contraceptives [see Nonclinical Toxicology].
The safety and effectiveness of JOURNAVX has not been established in pediatric patients.
Of the total 1130 patients with moderate to severe acute pain who received JOURNAVX in the Phase 3 studies [see Clinical Studies], 71 patients (6.3%) were 65 years of age and older.
Clinical studies of JOURNAVX did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. However, based on population pharmacokinetic analyses in patients with ages ranging from 18 to 75 years, age does not have a clinically relevant impact on suzetrigine exposure [see CLINICAL PHARMACOLOGY].
JOURNAVX has not been studied in patients with severe hepatic impairment. Avoid use of JOURNAVX in patients with severe hepatic impairment (Child-Pugh Class C) [see WARNINGS AND PRECAUTIONS]. The recommended JOURNAVX dosage is lower in patients with moderate hepatic impairment (Child-Pugh Class B) [see DOSAGE AND ADMINISTRATION] than those with normal hepatic function. The recommended dosage in patients with mild hepatic impairment (Child-Pugh Class A) is the same as those with normal hepatic function.
Patients with moderate hepatic impairment had greater suzetrigine and M6-SUZ (the active metabolite) exposure than those with normal hepatic function [see CLINICAL PHARMACOLOGY], which may increase the risk of suzetrigine adverse reactions.
JOURNAVX has not been studied in patients with renal impairment of eGFR < 15 mL/min. Avoid use of JOURNAVX in patients with renal impairment of eGFR < 15 mL/min [see CLINICAL PHARMACOLOGY]. The recommended dosage in patients with eGFR > 15 mL/min is the same as those with normal kidney function.
No specific antidote is available for overdose with JOURNAVX. Treatment of overdose consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.
Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated [see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS].
Suzetrigine is a selective blocker of the NaV1.8 voltage-gated sodium channel, compared to other known voltage-gated sodium channels (NaV1.1 through 1.9). NaV1.8 is expressed in peripheral sensory neurons including dorsal root ganglion neurons, where its role is to transmit pain signals (action potentials). By selectively inhibiting NaV1.8 channels, suzetrigine inhibits transmission of pain signals to the spinal cord and brain. M6-SUZ, a major active metabolite, is a less potent inhibitor of NaV1.8 than suzetrigine by 3.7-fold.
At 2 times the exposure of the maximum recommended JOURNAVX dose, clinically significant QTc prolongation was not observed.
The pharmacokinetic parameters for suzetrigine and its major active metabolite, M6-SUZ, are shown in Table 4.
Table 4: Pharmacokinetic Parameters of Suzetrigine and M6-SUZ
| Suzetrigine | M6-SUZ (Active Metabolite)a | |
| General Information | ||
| Steady State AUC0-24h (CV%), μg*h/mL | 11.5 (25.6%) | 34.7 (25.6%) |
| Steady State Cmax (CV%), μg/mL | 0.62 (27.7%) | 1.5 (24.5%) |
| Time to 90% Steady State, days | 3 | 5 |
| Mean (CV%) Accumulation Ratio b | 3.4 (30.2%) | 4.5 (30.6%) |
| Absorption | ||
| Median Tmax (range), hours | 3.0 hours (1.50, 5.03) | 10.0 hours (4.0, 48.1) |
| Distributionc | ||
| Mean (CV%) Apparent Volume of Distribution, L | 495 (25.0%) | NA |
| Protein Binding | 99% | 96% |
| Elimination | ||
| Mean (CV%) Effective Half-Life, hours b | 23.6 (36.2%) | 33.0 (34.9%) |
| Steady State Mean (CV%) Apparent Oral Clearance, L/hours | 13.9 (37.5%) | NA |
| Metabolism | ||
| Primary Pathway | CYP3A | CYP3A |
| Excretion | ||
| Primary Pathway |
|
|
| AUC: area under the concentration versus time curve; CV: coefficient of variation; Cmax: maximum observed concentration; Tmax: time of maximum concentration; NA: not applicable a Based on an in vitro electrophysiology assay in human dorsal root ganglion neurons, M6-SUZ is a less potent inhibitor of NaV1.8 than suzetrigine by 3.7-fold. b Based on simulations of a dose of 50 mg every 12 hours (q12h). c Suzetrigine and M6-SUZ do not partition preferentially into human red blood cells. |
||
Effect Of Food
Administration of 100 mg of JOURNAVX (the first dose) with a high-fat meal (800 to 1000 calories, 50% derived from fat), a moderate-fat meal (600 calories, 30% derived from fat), and a low-fat meal (up to 500 calories with no more than 25% derived from fat) resulted in decreased initial concentrations of suzetrigine and M6-SUZ in comparison to a fasted state. The median Tmax of suzetrigine and M6-SUZ in the fasted state was 3 hours and 8 to 10 hours, respectively. When administered in the fed state (high-fat meal or moderate-fat meal) the median Tmax of suzetrigine was delayed to 5 hours and the median Tmax of M6-SUZ was delayed to 24 hours. The Cmax and AUC of suzetrigine and M6-SUZ were not affected by any of the meal conditions, including a high-fat meal consumed one hour after JOURNAVX administration.
Administration of the second JOURNAVX dose of 50 mg with or without regard to meals is predicted to not affect the systemic exposures of suzetrigine and M6-SUZ.
No clinically significant differences in pharmacokinetics of suzetrigine and M6-SUZ were observed based on age (18-75 years), sex, body weight (44-126 kg), race, and renal impairment (eGFR ≥ 15 mL/min by CKD-EPI equation with adjustment for the body surface area). The effect of renal impairment with eGFR < 15 mL/min on suzetrigine and M6-SUZ pharmacokinetics is unknown.
In patients with mild hepatic impairment (Child-Pugh Class A), no clinically significant differences in pharmacokinetics of suzetrigine and M6-SUZ were observed. In patients with moderate hepatic impairment (Child-Pugh Class B), at steady state, suzetrigine AUC0-12h increased by 1.5-fold (90% CI: 1.1-2.1) and Cmax increased by 1.3-fold (90% CI: 1.0-1.7) and M6-SUZ AUC0-12h and Cmax both increased by 1.2-fold (AUC 90% CI: 0.83-1.6; Cmax 90% CI: 0.84-1.6). The effect of severe hepatic impairment (Child-Pugh Class C) on suzetrigine and M6-SUZ pharmacokinetics is unknown.
Strong CYP3A Inhibitors
Concomitant administration of itraconazole (a strong CYP3A inhibitor) with a single dose of JOURNAVX increased the geometric mean (90% CI) AUC0-inf of suzetrigine and M6-SUZ by 4.8-fold (4.3-5.4) and 4.4-fold (3.6-5.4), respectively, while the geometric mean (90% CI) Cmax of suzetrigine increased by 1.5-fold (1.3-1.6) and Cmax of M6-SUZ decreased by 32% (24-39%) [see DRUG INTERACTIONS].
Moderate CYP3A Inhibitors
Concomitant administration of fluconazole (a moderate CYP3A inhibitor) with JOURNAVX with the recommended dosage modification [see DOSAGE AND ADMINISTRATION] is predicted to increase the geometric mean (90% CI) AUCtau of suzetrigine and M6-SUZ by 1.5-fold (1.4-1.5) and 1.2-fold (1.2-1.3), respectively, while the geometric mean (90% CI) Cmax of suzetrigine and M6-SUZ is predicted to increase by 1.4-fold (1.4-1.5) and 1.1-fold (1.1-1.2), respectively, when compared to the regular recommended dosage in the absence of fluconazole [see DOSAGE AND ADMINISTRATION, DRUG INTERACTIONS].
Strong CYP3A Inducers
Concomitant administration of rifampin (strong CYP3A inducer) at steady state with a single dose of JOURNAVX decreased the geometric mean (90% CI) AUC0-inf of suzetrigine and M6-SUZ by 93% (91-94%) and 85% (83-86%), respectively, while the geometric mean (90% CI) Cmax of suzetrigine decreased by 80% (75-83%) and the Cmax of M6-SUZ increased by 1.3-fold (1.1-1.5) [see DRUG INTERACTIONS].
Moderate CYP3A Inducers
Concomitant administration of efavirenz (moderate CYP3A inducer) with a single dose of JOURNAVX is predicted to decrease the geometric mean (90% CI) AUC0-t of suzetrigine and M6-SUZ by 63% (61-65%) and 60% (58-62%), respectively, while the geometric mean (90% CI) Cmax of suzetrigine is predicted to decrease by 29% (27-32%) and M6-SUZ is predicted to increase by 1.3-fold (1.3-1.4), respectively [see DRUG INTERACTIONS].
Sensitive CYP3A Substrates
JOURNAVX administered 50 mg every 12 hours, at steady state decreased the geometric mean (90% CI) AUC0-inf of midazolam (sensitive CYP3A substrate) by 48% (43-53%) and Cmax by 37% (27-45%) [see DRUG INTERACTIONS].
Proton Pump Inhibitors
No clinically significant differences in suzetrigine and M6-SUZ pharmacokinetics were observed when JOURNAVX was used concomitantly with omeprazole.
Other Drugs
No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with JOURNAVX: oral digoxin (P-gp substrate), ethinyl estradiol (hormonal contraceptive), or levonorgestrel (hormonal contraceptive).
Cytochrome P450 (CYP450) Enzymes
Suzetrigine inhibits CYP2C8, CYP2C9, and CYP2C19, but is not expected to result in clinically significant drug interactions. Suzetrigine does not inhibit CYP1A2, CYP2B6, CYP2D6, and CYP3A enzymes, and M6-SUZ does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A enzymes. Suzetrigine induces CYP3A and to a lesser extent CYP2B6, CYP2C8, CYP2C9, and CYP2C19. Suzetrigine does not induce CYP1A2.
UDP-Glucuronosyltransferase (UGT)
Suzetrigine does not inhibit UGT1A1.
Transporter Systems
Suzetrigine and M6-SUZ are not substrates of BCRP, OATP1B1 or OATP1B3. Suzetrigine is not a P-gp substrate, but M6-SUZ is a P-gp substrate. Suzetrigine inhibits OATP1B1, OATP1B3 and OAT3 but is not expected to result in clinically significant drug interactions. Suzetrigine does not inhibit BCRP, OAT1, OCT2, MATE1, and MATE2/K transporters. M6-SUZ inhibits OATP1B1, OATP1B3, OAT1, and OAT3 but is not expected to result in clinically significant drug interactions. M6-SUZ does not inhibit P-gp, BCRP, OCT2, MATE1 and MATE2/K transporters.
The efficacy of JOURNAVX in the treatment of moderate to severe acute pain in adults was established in two randomized, double-blind, placebo and active-controlled trials of acute pain, one following full abdominoplasty (Trial 1) [see Clinical Studies] and the other following bunionectomy (Trial 2) [see Clinical Studies]. In each trial, pain intensity was measured using a patient-reported 11-point numeric pain rating scale (NPRS), ranging from 0 to 10, where zero corresponds to no pain and 10 corresponds to the worst pain imaginable.
Patients were eligible for study participation if they had moderate to severe pain on the verbal categorical rating system (VRS) and a pain score of ≥ 4 on the NPRS, within 4 hours of the abdominoplasty completion (Trial 1) or during the 9-hour period after discontinuation of regional anesthesia following bunionectomy (Trial 2). Once eligible, patients were randomized to receive oral JOURNAVX, placebo, or hydrocodone bitartrate/acetaminophen (HB/APAP) for a duration of 48 hours. For the JOURNAVX treatment regimen, patients received an initial loading dose of 100 mg JOURNAVX, followed by 50 mg every 12 hours. For the HB/APAP-control regimen, patients received 5 mg/325 mg every 6 hours. For both studies, 400 mg of ibuprofen every 6 hours, as needed for pain relief, was permitted as a rescue medication.
Trial 1 [NCT05558410] evaluated the efficacy of JOURNAVX over 48 hours in 1,118 adult patients with moderate to severe acute pain following a full abdominoplasty procedure (JOURNAVX n = 447, placebo n = 223, and hydrocodone bitartrate/acetaminophen (HB/APAP) n = 448). The majority of patients were female (98%), and the mean age was 42 years (range: 18 to 69). The study population consisted of 70% White participants, 27% Black or African American participants, 1% Asian participants, 0.8% Native Hawaiian or other Pacific Islander participants, 0.5% American Indian or Alaska Native participants, and 0.9% Other or Multiracial participants, among which 34% identified as Hispanic or Latino. The mean pain score at baseline was 7.4 (range: 4 to 10). All baseline characteristics, including NPRS, VRS, and BMI were generally balanced across treatment arms.
In Trial 1, 89% of patients in the JOURNAVX group completed the treatment period (compared to 75% of patients in the placebo group and 85% of patients in the HB/APAP group), and 9% of patients in the JOURNAVX group discontinued due to lack of efficacy (compared to 22% of patients in the placebo group and 13% of patients in the HB/APAP group).
Efficacy was evaluated by the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) in the JOURNAVX group compared to the placebo group and then to the HB/APAP group. Treatment with JOURNAVX demonstrated statistically significant superior reduction in pain compared to treatment with placebo (see Table 5).
In an exploratory analysis, the time-weighted sum of the pain intensity difference from 0 to 24 hours (SPID24) reported using the least square mean was 48.0 for the JOURNAVX group and 24.2 for the placebo group. The mean pain intensities over time are depicted for the JOURNAVX, placebo, and HB/APAP groups in Figure 1.
Table 5: SPID48 Results in Adults with Moderate to Severe Acute Pain Following Full Abdominoplasty (Trial 1)
| Efficacy Measure | JOURNAVX N = 447 |
Placebo N = 223 |
HB/APAPb N = 448 |
| LS mean a | 118.4 | 70.1 | 111.8 |
| LS Mean Difference vs placebo (95% CI) P value | 48.4 (33.6, 63.1) < 0.0001 | - | - |
| LS Mean Difference vs HB/APAP (95% CI) | 6.6 (-5.4, 18.7) | - | - |
| LS: Least Squares; CI: Confidence Interval a A larger value of LS mean indicates better efficacy measured by SPID48. b HB/APAP = hydrocodone bitartrate/acetaminophen |
|||
Figure 1: Mean Pain Intensity Over Time in Adults with Moderate to Severe Acute Pain Following Full Abdominoplasty (Trial 1)
 |
Note: Pre-rescue pain scores were carried forward for 6 hours following the use of rescue medication. HB/APAP = hydrocodone bitartrate/acetaminophen
The median time to meaningful pain relief (defined as a ≥ 2-point reduction in NPRS) was 119 minutes for patients in the JOURNAVX group and 480 minutes for patients in the placebo group. The median time to onset of perceptible pain relief (defined as a ≥ 1-point reduction in NPRS) for patients in the JOURNAVX group was 34 minutes.
Trial 2 [NCT05553366] evaluated the efficacy of JOURNAVX over 48 hours in 1,073 adult patients with moderate to severe acute pain following bunionectomy (JOURNAVX n = 426, placebo n = 216, and HB/APAP n = 431). The majority of patients were female (85%), and the mean age was 48 years (range: 18 to 75). The study population consisted of 71% White participants, 24% Black or African American participants, 2% Asian participants, 0.2% Native Hawaiian or other Pacific Islander participants, 1% American Indian or Alaska Native participants, and 1% Other or Multiracial participants, and 0.3% with race missing, among which 34% identified as Hispanic or Latino. The mean pain score at baseline was 6.8 (range: 4 to 10). All baseline characteristics, including NPRS, VRS, and BMI were generally balanced across treatment arms.
In Trial 2, 87% of patients in the JOURNAVX group completed the treatment period (compared to 82% of patients in the placebo group and 90% of patients in the HB/APAP group), and 12% of patients in the JOURNAVX group discontinued due to lack of efficacy (compared to 16% of patients in the placebo group and 8% of patients in the HB/APAP group).
Efficacy was evaluated by the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) in the JOURNAVX group compared to the placebo group and then to the HB/APAP group. Treatment with JOURNAVX demonstrated statistically significant superior reduction in pain compared to treatment with placebo (see Table 6).
In an exploratory analysis, the time-weighted sum of the pain intensity difference from 0 to 24 hours (SPID24) reported using the least square mean was 30.6 in the JOURNAVX group and 19.8 in the placebo group. The mean pain intensities over time are depicted for the JOURNAVX, placebo, and HB/APAP groups in Figure 2.
Table 6: SPID48 Results in Adults with Moderate to Severe Acute Pain Following Bunionectomy (Trial 2)
| Efficacy Measure | JOURNAVX N = 426 |
Placebo N = 216 |
HB/APAPb N = 431 |
| LS mean a | 99.9 | 70.6 | 120.1 |
| LS Mean Difference vs placebo (95% CI) P value |
29.3 (14.0, 44.6) 0.0002 |
- | - |
| LS Mean Difference vs HB/APAP (95% CI) | -20.2 (-32.7, -7.7) |
- | - |
| LS: Least Squares; CI: Confidence Interval a A larger value of LS mean indicates better efficacy measured by SPID48. b HB/APAP = hydrocodone bitartrate/acetaminophen |
|||
Figure 2: Mean Pain Intensity Over Time in Adults with Moderate to Severe Acute Pain Following Bunionectomy (Trial 2)
 |
Note: Pre-rescue pain scores were carried forward for 6 hours following the use of rescue medication. HB/APAP = hydrocodone bitartrate/acetaminophen
The median time to meaningful pain relief (defined as ≥ 2-point reduction in NPRS) was 240 minutes for patients in the JOURNAVX group and 480 minutes in the placebo group. The median time to onset of perceptible pain relief (defined as a ≥ 1-point reduction in NPRS) for patients in the JOURNAVX group was 60 minutes.
JOURNAVX
(jor na vix)
(suzetrigine) tablets, for oral use
What is JOURNAVX?
JOURNAVX is a prescription medicine used to treat adults with moderate to severe short-term (acute) pain.
It is not known if JOURNAVX is safe and effective in children.
Do not take JOURNAVX if you take certain medicines that are strong inhibitors of an enzyme called CYP3A. Ask your healthcare provider if you are not sure.
Before taking JOURNAVX, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Taking JOURNAVX with certain other medicines may affect the way JOURNAVX and the other medicines work and may increase your risk of side effects. See “Do not take JOURNAVX”. Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.
Especially tell your healthcare provider if you take:
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I take JOURNAVX?
What should I avoid while taking JOURNAVX?
Do not take food or drink containing grapefruit during treatment with JOURNAVX.
What are possible side effects of JOURNAVX?
The most common side effects of JOURNAVX include:
JOURNAVX may temporarily reduce the chance of females becoming pregnant while on treatment. Talk to your healthcare provider if you have concerns about becoming pregnant. If you are using contraceptives, you should continue to use contraceptives during treatment with JOURNAVX.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of JOURNAVX.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store JOURNAVX?
Store JOURNAVX at room temperature between 68°F to 77°F (20°C to 25°C).
Keep JOURNAVX and all medicines out of the reach of children.
General information about the safe and effective use of JOURNAVX.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use JOURNAVX for a condition for which it was not prescribed. Do not give JOURNAVX to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about JOURNAVX that is written for health professionals.
What are the ingredients in JOURNAVX?
Active ingredient: suzetrigine
Inactive ingredients: croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, and microcrystalline cellulose. The tablet film coat contains FD&C Blue #2 aluminum lake, polyethylene glycol, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.
This Patient Information has been approved by the U.S. Food and Drug Administration.
